ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types

Waltraut Lehmann, Dirk Mossmann, Julia Kleemann, Kerstin Mock, Chris Meisinger, Tilman Brummer, Ricarda Herr, Simone Brabletz, Marc P. Stemmler and Thomas Brabletz ()
Additional contact information
Waltraut Lehmann: University of Freiburg Medical Center
Dirk Mossmann: Faculty of Biology, Albert-Ludwigs-University Freiburg
Julia Kleemann: Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg
Kerstin Mock: University of Freiburg Medical Center
Chris Meisinger: Institute for Biochemistry and Molecular Biology, ZMBZ, Albert-Ludwigs-University Freiburg
Tilman Brummer: BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg
Ricarda Herr: Institute for Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg
Simone Brabletz: Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg
Marc P. Stemmler: Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg
Thomas Brabletz: Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg

Nature Communications, 2016, vol. 7, issue 1, 1-15

Abstract: Abstract Early dissemination, metastasis and therapy resistance are central hallmarks of aggressive cancer types and the leading cause of cancer-associated deaths. The EMT-inducing transcriptional repressor ZEB1 is a crucial stimulator of these processes, particularly by coupling the activation of cellular motility with stemness and survival properties. ZEB1 expression is associated with aggressive behaviour in many tumour types, but the potent effects cannot be solely explained by its proven function as a transcriptional repressor of epithelial genes. Here we describe a direct interaction of ZEB1 with the Hippo pathway effector YAP, but notably not with its paralogue TAZ. In consequence, ZEB1 switches its function to a transcriptional co-activator of a ‘common ZEB1/YAP target gene set’, thereby linking two pathways with similar cancer promoting effects. This gene set is a predictor of poor survival, therapy resistance and increased metastatic risk in breast cancer, indicating the clinical relevance of our findings.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/ncomms10498 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10498

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms10498

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().